Given the overall prevalence of irritable bowel syndrome, it is important for clinicians to be able to distinguish postinfectious irritable bowel syndrome from its other subtypes.
Further research is warranted to understand the potential ways fecal microbiota transplantations may improve patients’ responses to immunotherapy.
Reviewing a patient’s potential risk for osteoporosis should be a routine part of each visit for patients with IBD.
Due to the relatively high relapse rate and need for additional therapies, current research is being done on the use of Vedolizumab for the treatment of microscopic colitis.
The exact pathophysiology of microscopic colitis is not completely understood, though PPIs and NSAIDs are 2 medications commonly implicated for triggering the inflammatory process.
Current research indicates that short-term utilization of an LFD may help ameliorate some mild IBS symptoms associated with quiescent IBD, while further long term studies are still needed.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.
A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.
A team of investigators assessed the potential for use of proton pump inhibitors to affect the risk of COVID-19 infection.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
